Quick Read - CVX has raised its dividend for 39 straight years, with 2025 operating cash flow covering the $12.75B payout nearly 3 times. - In 2020's cash flow collapse, Chevron still paid $9.7B in dividends, backed by a debt-to-equity ratio of just 0.25. - Chevron hit record...<
Two firms raised Hinge Health’s price targets to $80 and $63 after reporting improved profitability and operational momentum. Citizens raised its price target for Hinge Health Inc. (HNGE) to $80 from $65, citing accelerating top-line growth and expanding profitability marg
Analysts raise price targets after Tango shifts focus to first-line pancreatic cancer therapy, anticipating key data later this year. Leerink increased its price target for Tango Therapeutics (NASDAQ:TNGX) to $55 from $28, maintaining an Outperform rating following first-q
Erasca Inc. (NASDAQ:ERAS) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 11, Erasca Inc. (NASDAQ:ERAS) announced a supply agreement and a clinical trial partnership with Merck The collaboration is aimed at facilitating the
DYN submits Biologics License Application for z-rostudirsen, seeking Priority Review to shorten FDA approval timeline to six months. Dyne Therapeutics (NASDAQ:DYN) submitted its Biologics License Application to the FDA for z-rostudirsen, a treatment for Duchenne muscular d
Mineralys Therapeutics reports lorundrostat achieved significant systolic blood pressure reductions in Phase 3 trials ahead of FDA review. Mineralys Therapeutics (NASDAQ:MLYS) announced Phase 3 trial results for lorundrostat, demonstrating placebo-adjusted systolic blood p
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On June 2, Praxis Precision Medicines Inc. (NASDAQ:PRAX) published the findings of its extensive Phase 2/3 POWER1 study This research ev
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 21, Cantor Fitzgerald analyst Kristen Kluska maintained an Overweight rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and raised t
Dianthus Therapeutics Inc. (NASDAQ:DNTH) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 7, Raymond James increased its price target on Dianthus Therapeutics Inc. (NASDAQ:DNTH) from $123 to $125 The firm also reiterated its
SpaceX (SPCX) is gearing up for the largest IPO in stock market history. But millions of investors may soon find Elon Musk's aerospace giant in their portfolios — whether they choose to buy the stock or not The reason? New index rules at Nasdaq and Russell slash tra
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.